A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

PURPOSE: A phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was designed to collect FDA-required safety/toxicity data...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Immunol
Hauptverfasser: Ozkaynak, M. Fevzi, Gilman, Andrew L., London, Wendy B., Naranjo, Arlene, Diccianni, Mitchell B., Tenney, Sheena C., Smith, Malcolm, Messer, Karen S., Seeger, Robert, Reynolds, C. Patrick, Smith, L. Mary, Shulkin, Barry L., Parisi, Marguerite, Maris, John M., Park, Julie R., Sondel, Paul M., Yu, Alice L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2018
Schlagworte:
Immunology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6016521/
https://ncbi.nlm.nih.gov/pubmed/29967609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01355
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge